It is in doctors’ and the drug industry’s best interests that their interactions be openly declared
There is no such thing as a free lunch. Pharmaceutical companies lavish meals, five-star travel, cash and gifts on doctors for one reason: to encourage them to prescribe their drugs. The standard retort from the medical profession is that doctors have sufficient clinical objectivity — and personal integrity — not to be so crudely swayed. Perhaps so.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Stop the gravy train [editorial]. Sydney Morning Herald 2006; 7 Aug: 8.
- 2. Moynihan R. The sugar-coated pill. The Australian 2006; 25 July: 10.
- 3. Wanzana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000; 283: 373-380.
- 4. Kassirer JP. On the take. How medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press, 2005.
- 5. Moynihan R. Doctor treats to be disclosed. The Australian 2006; 26 Jul.
- 6. Rogers C. The necessary and sufficient conditions of therapeutic personality change. J Consult Psychol 1957; 21: 95-103.
- 7. Giddens A. The consequences of modernity. Cambridge: Polity Press, 1990.
- 8. Baier A. Trust and antitrust. In: Moral prejudices: essays on ethics. Cambridge, Mass: Harvard University Press, 1955.
- 9. O’Neill O. Autonomy and trust in bioethics. Cambridge: Cambridge University Press, 2002.
- 10. Little JM. Community, security and human flourishing: an exploratory essay. Sydney: Centre for Values, Ethics and the Law in Medicine, 2004.
- 11. Gilson L. Trust and the development of health care as a social institution. Soc Sci Med 2003; 56: 1453-1468.
- 12. Thompson D. Understanding financial conflicts of interest. N Engl J Med 1993; 329: 573-576.
- 13. Pearson SD, Kleinman K, Rusinak D, Levinson W. A trial of disclosing physicians’ financial incentives to patients. Arch Intern Med 2006; 166: 623-628.
- 14. Breen KJ. The medical profession and the pharmaceutical industry: when will we open our eyes? Med J Aust 2004; 180: 409-410. <MJA full text>
- 15. Tattersall M, Kerridge I. The drug industry and medical professionalism. Lancet 2006; 367: 28.
None identified.